United States enablementgenus claimssection 112

Amgen Inc v Sanofi

598 US 594 (2023)

JurisdictionUnited States

CourtSupreme Court of the United States

Year2023

StatusBinding authority

Key Principle

The enablement requirement of 35 USC §112 demands that the patent specification enable the full scope of the claimed genus, not just a few species; broad functional claims to an entire genus of antibodies were invalid for lack of enablement.

Area of Law

Related Cases

Warner Chappell Music Inc v Nealy 601 U.S. 366 (2024)

Vidal v Elster 602 U.S. 286 (2024)

Andy Warhol Foundation for the Visual Arts Inc v Goldsmith 598 U.S. 508 (2023)

Ask CommonBench about this case

Get a detailed analysis of Amgen Inc v Sanofi and how it applies to your situation.

Explain Amgen Inc v Sanofi